Acoramidis yields a significantly better four-step primary hierarchical outcome, including aspects of mortality and morbidity, than placebo for patients with transthyretin amyloid cardiomyopathy, according to a study published in the Jan. 11 issue of the New England Journal of Medicine.
from Medical Xpress - latest medical and health news stories https://ift.tt/teGYH8W
